I see these questions come up on social media, but they

New Post Public Reply Private Reply Replies (0) Message Board
redspeed
283
I see these questions come up on social media, but they have already been answered. For new investors, it may be helpful.

Why do the Tollovid trial in Israel?

"Every single company on the planet has been focused on getting data in Israel. They all laughed when we started because natural… as they have failed, no one laughing anymore. Data will come and focus is on its quality"

Why small trial size? Pfizer is so much larger?

When GC was, I guess told by an investor on twitter Jan. 1: "Going to be hard to show or have any kind of P value with just 30 patients"

GC responded also on New Years Day:
"Not in hospital setting. no. Outpatient I would agree. Everyone needs to understand fundamental difference , but showing benefit in hospital very bullish for outpatient."

For something like Covid where patients are dying in hospitals, you are not going to have a phase 2 with thousands in a few months. Show results that it reduced days in hospitals and also show the effectiveness with biomarkers and outpatient is unlimited potential. Or you can do like Pfizer and start with 'healthy' people first and just go after outpatient.

If Todos wants to do a pivotal 2/3, how long does that take?

Guess it would depend on whether Todos does inpatient or the easier path of outpatient like Pfizer

Pfizer outpatient went pretty quick from 1st participant in Sept to Interim data in November. 2 months


March 23, 2021 Pfizer Initiated Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2. Phase 1 study was in HEALTHY adults to evaluate the safety, tolerability, and pharmacokinetics of the investigational compound.

September 1, 2021 Pfizer dosed the first participant in a pivotal Phase 2/3

The randomized, double-blind trial planned on enrolling approximately 1,140 participants, who received the drugs or placebo orally every 12 hours for five days.

November 5, 2021 Pfizer annouced their COVID-19 Oral Antiviral Treatment reduced risk of hospitalization or death by 89% in their interim analysis

December 22, 2021 Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment

What edge does Todos have over Pfizer's pills?

In addition to the anti-cytokine properties which I believe Pfizer's doesn't have and why they are went after out patient Paxlovid has side effects and their treatment has risks.

Q. Are there potential side effects of Paxlovid?
A. Possible side effects of Paxlovid include dysgeusia (altered or impaired sense of taste), diarrhea, increased blood pressure, and myalgia (muscle aches).
Nirmatrelvir and ritonavir, which comprise Paxlovid, also interact with other medicines, which may lead to serious or life-threatening adverse reactions. Patients should tell their health care providers all of the
medicines they are taking, including over-the-counter medications and herbal supplements, when deciding whether to take Paxlovid.
Liver problems have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering Paxlovid to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis. Patients should talk with their health care provider if they have a history of liver problems.

Paxlovid is not recommended for patients with severe kidney problems, and a different dose is needed for patients with moderate kidney problems. Patients should talk with their health care provider if they have a history of kidney problems.
Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.
Patients with HIV who are not on treatment with “undetectable” viral load should talk with their health care provider before taking Paxlovid.
There are limited clinical data available for Paxlovid. Serious and unexpected adverse events may occur that have not been previously reported with Paxlovid use.

I heard Ivermectin has a 3CL protease inhibitor and it's cheap. Can't I load up on that to get the same effects of Paxlovid or Tollovid?

According to the company, you would have to take toxic levels to get close to the same level. Also neither of the other two have strong anti-cytokine activity.


Ivermectin Fans Have a New Champion to Root For - 3CL Protease Inhibitor Tollovid
https://www.zerohedge.com/news/2021-12-15/ive...r-tollovid



Todos Med Ltd. (TOMDF) Stock Research Links

TOMDF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 365

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 381

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 414

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 360

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 215

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 190

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 472

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 190

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 485

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
7th World Media Summit Spotlights Media's Future in Beijing

Updated Category News Views 235

The Changing Landscape of Global Media An event of this magnitude doesn't just pop up every day like a stock ticker on Wall Street. This year's 7th World Media Summit in Beijing is where nearly 500 bigwigs from all corners of the media landscape are converging. It's not about trading stocks or hitting quarterly numbers—it's about shaping how stories get told in an era...

Continue Reading

Top 5 Most Recently Viewed Articles

VITA Revolutionizes Urban Development for Luxury Living

Updated Category News Views 288

VITA Revolutionizes Urban Development for Luxury Living VITA, a renowned global design firm specializing in land planning, real estate strategy, community design, hospitality design, and landscape architecture, has become a key player in shaping luxury projects across urban locales. Their innovative work has facilitated the sale of over $20 billion in residential real...

Continue Reading
Neon Bloom, Inc. Unveils New AI-Powered Payment Solutions

Updated Category News Views 213

Innovative AI-Driven Payment Processing at Neon Bloom Neon Bloom, Inc. (OTC: NBCO) has made headlines with its successful launch of a cutting-edge AI-driven backend software for its payment processing platforms. The software, developed by its subsidiary Advance Executive Sales, marks a significant advancement in their operations and response to market demands. Key...

Continue Reading
Bank of America Announces Preferred Stock Dividends for 2025

Updated Category News Views 290

Bank of America’s Preferred Stock Dividend Announcement Bank of America Corporation has made a significant announcement regarding its preferred stock dividends, highlighting the commitment to delivering value to its investors. The Board of Directors has approved regular cash dividends on various series of preferred stock which will benefit shareholders in the upcoming...

Continue Reading
Rowspace Raises $50M to Revolutionize Financial Decision-Making

Updated Category News Views 371

Investing in Intelligence: The Launch of Rowspace In a world where every second and every decision can mean millions, Rowspace's recent debut is like fresh air in a stuffy boardroom. The fintech landscape just got a shot in the arm with a hefty $50 million backing from high-profile investors—Sequoia leading the charge. This funding isn't just pocket change; it's a...

Continue Reading
Understanding Microsoft's Option Trends for Savvy Investors

Updated Category News Views 190

Understanding Microsoft's Option Trends for Savvy Investors Investors looking for opportunities have shown a bullish outlook regarding Microsoft (NASDAQ: MSFT). This heightened activity is noteworthy, indicating that significant players in the market have made some critical moves, which could be crucial for retail traders to watch. The recent trades observed reflect a...

Continue Reading